Nicholas C. Nicolaides, Ph.D. is the President, Chief Executive Officer and co-founder of Navrogen Inc. Prior to co-founding Navrogen, he was President, CEO and co-founder of Morphotek Inc., a private biopharmaceutical company specializing in the development of protein and antibody therapeutics through the use of a proprietary gene evolution technology. Morphotek was acquired by Eisai, Co. Ltd. in 2007. From 2007 to 2018, he remained President and CEO of Morphotek as it operated as an autonomous subsidiary of Eisai. Prior to co-founding Morphotek, he was Director of R&D at Magainin Pharmaceuticals Inc. He is a trained molecular geneticist and has authored over 70 peer-reviewed scientific papers on the molecular and genetic basis of cancer, respiratory disease and drug development and is an inventor on 75 issued patents.
Nick received a B.S. in Biology from St. Joseph’s University, Philadelphia, PA; a Ph.D. in Human Genetics from Thomas Jefferson University, Philadelphia, PA; and a Fellowship in Oncology from Johns Hopkins University, Baltimore, MD. While at Johns Hopkins, his research resulted in the discovery of the genetic cause of one of the most common forms of inherited cancer. He has been recognized by R&D Directions’ as one of the Top 20 Most Notable People in Research and Development and received the Ernst & Young’s Entrepreneur of the Year award. In 2013 he received the Pennsylvania Governor’s Entrepreneur Impact Award for his successful accomplishments in expanding Morphotek’s operations and bringing international investment into the Pennsylvania Common Wealth. He currently serves as an ad hoc reviewer for several immunology and cancer research journals; is a member of the American Association for Cancer Research and New York Academy of Sciences; serves on the Dean’s Advisory Board of St. Joseph’s University; is on the Board of Directors of the publicly traded specialty pharma Egalet Inc and the privately held, oncology-focused biopharma Cage Pharmaceuticals; and is a member of several philanthropic organizations supporting the advancement of education and individuals with disabilities.